Skip to main content

Advertisement

Table 1 Patient characteristics

From: Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)

Characteristics Study population (n = 246)
Median age (range), years 50 (23–81)
Stage cT1 59 24%
cT2 140 57%
cT3/4 47 19%
cN0 120 49%
cN+ 124 50%
Nx 2 1%
Tumor grading G1–2 106 43%
G3 139 57%
Ki-67 ≤ 20% 48 20%
> 20% 154 63%
Unknown 44 18%
Subtypea Luminal A-like 57 23%
Luminal B-like 29 12%
HER2+/HR- 33 13%
HER2+/HR+ 37 15%
Triple-negative 90 37%
Histology Ductal 201 82%
Lobular 17 7%
Other subtypes 28 11%
Neoadjuvant therapy Anthracycline-based and taxane-based 225 92%
Anthraycycline-based 2 < 1%
Taxane-based 18 7%
Trastuzumab 67b 27%
Pertuzumab 23c 9%
Type of surgery Breast conserving 179 73%
Mastectomy 66 27%
MRI Baseline MRI 234 95%
1.5 Tesla after NACT 112 45%
3.0 Tesla after NACT 123 50%
Radiologic response rCR 111 45%
rPR 121 49%
rSD 8 3%
rPD 6 2%
Pathologic response pCR 71 29%
no pCR 175 71%
Adjuvant therapy Additional chemotherapy 5 2%
Endocrine therapy 109d 44%
Trastuzumab 63e 26%
  1. NACT neoadjuvant chemotherapy, rCR radiologic complete response, rPR radiologic partial response, rSD radiologic stable disease, rPD radiologic progressive disease, pCR pathologic complete response, HER2 human epidermal growth factor receptor 2, MRI magnetic resonance imaging
  2. aDefined by immunohistochemical analysis: luminal A-like was defined as hormone receptor (HR)-positive, HER2 negative, grade (G) 1–2 and Ki-67 < 20% (if available); luminal B-like was defined as HR-positive, HER2 negative, G2 and Ki-67 ≥ 20% or G3
  3. b96% of patients with HER2-positive tumors
  4. c33% of patients with HER2-positive tumors
  5. d85% of patients with HR+ tumors
  6. e87% of patients with HER2-positive tumors